News and Events

Our colleagues Dr. Olena Mishchuk, Director of Business Development, Asia Pacific Region, and Dr. Iaroslava Kos, Director of Business Development at Enamine, will be available at the CPHI Korea conference from August 27-29 in Seoul.

Compounds containing 1,3-Benzodioxole are known for inhibiting the COX enzyme and cytotoxic effects against cancer cells such as cervical cells. Check out our selection of 1,3-Benzodioxole-based building blocks to enhance your research.

Do not miss out — order today and take your projects to the next level!

Have you been missing our #MeetChemspaceTeam post series? Say hello to our Account Manager – Viktor Korniienko! Click the link to discover more about him.

Tulmimetostat is a selective and orally bioavailable Enhancer of Zeste Homolog 2 (EZH2) inhibitor, that demonstrates promising potential in treating hematologic malignancies and solid tumors. Discover a set of analogs for Tulmimetostat to expand further research.

Did you miss any of our July news and highlights? Here is a comprehensive summary of our posts for this month!

Explore a selected Biological Products Set from Chemspace for studying Orexin receptors, which is pivotal in treating major depressive disorder and insomnia. Follow the link to check out the comprehensive selection at Chemspace Biologics!

Great news! All our flyers, posters & press releases are now in one place. Check them out and download the latest materials.

The latest issue of the "Building Blocks for Drug Candidates" series! Discover analogs to a core of Fosigotifator, a promising treatment for Amyotrophic Lateral Sclerosis  - a rare and fatal neurological condition.

Hot News for the Hot Season! From now on all special offers are in one place! Do not wait - follow the link and discover all the terms and conditions.

Meet Halyna Hrodziuk – our Account Manager! Follow the link to learn about Halyna closer. 

Ifebemtinib – a highly selective, orally bioavailable FAK (focal adhesion kinase) inhibitor discovered by Boehringer Ingelheim and developed by InxMed, shows significant potential as a cancer therapy. Follow the link to explore a set of analogs from Chemspace.

Here is a summary of all Chemspace news and highlights for June, in case you missed it.

The future of DUB research is promising, with the potential for discovering safe and effective cancer therapy inhibitors and beyond. Discover DUBs from Biortus on our comprehensive Biologics platform.

Rita Gaidar and Anna Kapeliukha send best wishes from RICT 2024! Stop by our posters #P135 and #P92 to explore collaboration opportunities.

Molsoft's new GINGER software generates high-quality conformer libraries super fast on GPUs. Combined with Enamine REAL products, we at Chemspace offer unique services like RIDE and RIDGE screenings. Learn more about our Virtual Screening services here.

We are excited to participate in RICT 2024 in Bordeaux, France, from July 3-5. Schedule a meeting with us to discuss potential collaboration.

Summer special offer: buy antibodies and get free samples from ProSci! All the details here.

The latest issue of the "Building Blocks for Drug Candidates" series! Discover key analogs to a potential drug - Seltorexant, a promising treatment for major depressive disorder and insomnia.

Our General Pre-Plated Library now includes over 862K molecules. Explore and download it now.

Check out the latest Chemspace co-authored article, exploring how AlphaFold2 models expand the realm of structure-based ligand discovery!

Join Olena Strapak at the 38th ACS National Medicinal Chemistry Symposium in Seattle on June 23-26! Schedule a personal meeting to discover potential collaboration opportunities.

Get a CCK-8 kit (1 ml, 100 tests) from TargetMol for just 1 USD/EUR with any order. Read more here.

Check out our latest Biologics campaign post, focusing on Spleen Tyrosine Kinase (Syk). Follow the link and explore a set of Chemspace Biologics specially selected for studying Syk-related diseases. 

Have you been missing our 'Weekend article' feature? If so, we have a treat for you! Follow the link below to explore a new approach to creating dual agonists using Machine Learning.